Skip to content
DataLookout
Menu

Hangzhou Sumgen Biotech Co., Ltd. clinical trial pipeline

Get alerts when Hangzhou Sumgen Biotech Co., Ltd.'s trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

  1. Notable: SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab · Advanced Solid Tumors Recruitment opened Hangzhou Sumgen Biotech Co., Ltd.Phase 1/2 NCT07774611
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Active trials by phase

Phase 1
2
Phase 1/2
2
Phase 2
3
Phase 3
1

Disease areas by active trials

Get alerts when Hangzhou Sumgen Biotech Co., Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free